Nivoix Yasmine, Velten Michel, Letscher-Bru Valérie, Moghaddam Alireza, Natarajan-Amé Shanti, Fohrer Cécile, Lioure Bruno, Bilger Karin, Lutun Philippe, Marcellin Luc, Launoy Anne, Freys Guy, Bergerat Jean-Pierre, Herbrecht Raoul
Pharmacie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Clin Infect Dis. 2008 Nov 1;47(9):1176-84. doi: 10.1086/592255.
Invasive aspergillosis is associated with high death rates. Factors associated with increased mortality have not yet been identified in a large population of patients with various underlying conditions.
We retrospectively reviewed 385 cases of suspected or documented aspergillosis that occurred during a 9-year period. We identified 289 episodes that fulfilled the criteria for possible, probable, or proven invasive aspergillosis according to the international definition criteria and that was treated with an anti-Aspergillus active antifungal drug. Clinical and microbiological variables were analyzed for their effects on overall and attributable mortality. Significant variables in univariate analysis were introduced into a multivariate Cox model.
Twelve-week overall and disease-specific survival rates were 52.2% (95% confidence interval, 46.5%-57.9%) and 59.8% (95% confidence interval, 54.0%-65.4%), respectively. Receipt of allogeneic hematopoietic stem cell or solid-organ transplant, progression of underlying malignancy, prior respiratory disease, receipt of corticosteroid therapy, renal impairment, low monocyte counts, disseminated aspergillosis, diffuse pulmonary lesions, pleural effusion, and proven or probable (as opposed to possible) aspergillosis are predictors of increased overall mortality. Similar factors are also predictors of increased attributable mortality, with the following exceptions: pleural effusion and low monocyte counts have no impact, whereas neutropenia is associated with a higher attributable mortality.
Identification of predictors of death helps in the identification of patients who could benefit from more-aggressive therapeutic strategies. Initiation of therapy at the stage of possible infection improves outcome, and this finding calls for the development of efficient preemptive strategies to fill the gap between empirical and directed therapy.
侵袭性曲霉病与高死亡率相关。在患有各种基础疾病的大量患者中,尚未确定与死亡率增加相关的因素。
我们回顾性分析了9年间发生的385例疑似或确诊的曲霉病病例。根据国际定义标准,我们确定了289例符合可能、很可能或确诊侵袭性曲霉病标准且接受了抗曲霉活性抗真菌药物治疗的病例。分析临床和微生物学变量对总死亡率和归因死亡率的影响。将单因素分析中的显著变量纳入多变量Cox模型。
12周的总生存率和疾病特异性生存率分别为52.2%(95%置信区间,46.5%-57.9%)和59.8%(95%置信区间,54.0%-65.4%)。接受异基因造血干细胞或实体器官移植、基础恶性肿瘤进展、既往呼吸系统疾病、接受皮质类固醇治疗、肾功能损害、单核细胞计数低、播散性曲霉病、弥漫性肺部病变、胸腔积液以及确诊或很可能(而非可能)的曲霉病是总死亡率增加的预测因素。类似因素也是归因死亡率增加的预测因素,但有以下例外:胸腔积液和单核细胞计数低没有影响,而中性粒细胞减少与较高的归因死亡率相关。
确定死亡预测因素有助于识别可能从更积极治疗策略中获益的患者。在可能感染阶段开始治疗可改善预后,这一发现呼吁制定有效的抢先治疗策略,以填补经验性治疗和针对性治疗之间的差距。